SAL003

Asset

PCSK9 inhibitor antibody evaluated in combination with atorvastatin for dyslipidemia

Stage: Phase 2
Modality: Antibody
Target: Lipid and ceramide metabolism; 1
Indication: 557
Trials: 1
Developer

Indications

1

Hypercholesterolemia and mixed dyslipidemia
Phase 2, Completed, NCT07278830, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains3
Owner and partners1
Trials557
Evidence for its targets3
Competitors12
Signals11

Every asset’s record: target, stage, trials and the evidence behind it.